CN Patent

CN120882712A — Rock2抑制剂

Assigned to Greweton Biotechnology Co ltd · Expires 2025-10-31 · 1y expired

What this patent protects

本公开涉及Rho相关蛋白激酶(ROCK)的抑制剂、包含所述抑制剂的药物组合物及其用于预防或治疗由所述ROCK介导的疾病的用途。特别是，所述ROCK的抑制剂对ROCK2的抑制具有选择性。

USPTO Abstract

本公开涉及Rho相关蛋白激酶(ROCK)的抑制剂、包含所述抑制剂的药物组合物及其用于预防或治疗由所述ROCK介导的疾病的用途。特别是，所述ROCK的抑制剂对ROCK2的抑制具有选择性。

Drugs covered by this patent

belumosudil-mesylate (BELUMOSUDIL MESYLATE)

Patent Metadata

Patent number: CN120882712A
Jurisdiction: CN
Classification: —
Expires: 2025-10-31
Drug substance claim: No
Drug product claim: No
Assignee: Greweton Biotechnology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.